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Abstract: A meeting among expert pathologists was held in 2019 in Rome to verify the results
of the previous harmonization efforts on the PD-L1 immunohistochemical testing by scoring
a representative series of non-small cell lung cancer (NSCLC) digital slides. The current paper
shows the results of this digital experimental meeting and the expertise achieved by the community
of Italian pathologists. PD-L1 protein expression was determined using tumor proportion score
(TPS), i.e., the percentage of viable tumor cells showing partial or complete membrane staining at any
intensity. The gold standard was defined as the final PD-L1 score formulated by a panel of seven
lung committed pathologists. PD-L1 status was clustered in three categories, namely negative (TPS
< 1), low (TPS 1–49%), and high (TPS ≥ 50%). In 23 cases (71.9%) PD-L1 staining was performed
using the companion diagnostic 22C3 pharmDx kit on Dako Autostainer, while in nine (28.1%)
cases it was performed using the SP263 Ventana kit on BenchMark platform. A complete PD-L1
scoring agreement between the panel of experts and the participants was reached in 57.1% of cases,
whereas a minor disagreement in 16.1% of cases was recorded. Italian pathologists performed best in
strong positive cases (i.e., tumor proportion score TPS > 50%), whereas only 10.8% of disagreement
with the gold standard was observed, and 55.6% regarded a single challenging case. The worst
performance was achieved in the negative cases, with 32.0% disagreement. A significant difference
resulted from the analysis of the data separated by the different clones used: 22.3% and 38.1%
disagreement (p = 0.01) was found in the group of cases analyzed by 22C3 and SP263 antibody
clones, respectively. In conclusion, this workshop record proposed the application of a digital
pathology platform to share controversial cases in educational meetings as an alternative possibility
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for improving the interpretation and reporting of specific histological tools. Due to the crucial role
of PD-L1 TPS for the selection of patients for immunotherapy, the identification of unconventional
approaches as virtual slides to focus experiences and give more detailed practical verifications of
the standard quality reached may be a considerable option.
Keywords: PD-L1; immunotherapy; NSCLC
1. Introduction
During the last two decades, a significant revolution in pathology laboratories has been represented
by the implementation of whole slide imaging and digital scanners [1]. Digital pathology may play
a significant role as a didactic, diagnostic and research tool. In fact, digital slides are more efficient
to adequately replicate the microscope experience than static images [2]. Another advantage in this
setting is represented by the possibility to highlight and analyze interesting areas during didactic
sessions [2]. Despite a more realistic experience can be obtained by adopting multi-headed microscopes,
a limitation in this approach is related by the low number of viewing head extensions (5 to 14) [2] while
digital slides may allow, by using dedicated monitor, an adequate experience to a higher number of
attendants [3].
The evaluation of the diagnostic performances of a single tissue biomarker like programmed
death-ligand 1 (PD-L1) seems to be a good opportunity to test in parallel the application of digital
pathology as a routine tool in educational programs.
PD-L1 immunohistochemical (IHC) testing plays an essential role to select advanced stage
non-small cell lung cancer (NSCLC) patients for treatment with immune system checkpoint inhibitors [4–
6]. In this setting, standardization of both pre-analytical and analytical procedures is a crucial, albeit not
trivial, task. Several antibodies have been adopted for PD-L1 staining and usually developed on different
immunostainers. The most reproducible results were obtained with the 22C3 (Dako, Carpinteria, CA,
USA), 28-8 (Dako), and SP263 clones (Ventana, Tucson, AZ, USA) [7,8]. So far, a constellation of many
different research papers has been published to harmonize and standardize PD-L1 IHC assays [9–11].
However, interpretation remains challenging, and specific expertise is required to correctly assess PD-L1
status [12–16]. Various clinical interests converge towards the continuous education of pathologists in
improving the reproducibility of PD-L1 analysis.
The evaluation of the diagnostic performance of a single tissue biomarker such as PD-L1 in
NSCLC is a paradigmatic opportunity to implement digital pathology in highly specialized educational
programs. For this purpose, a working group of Italian pathologists met in 2019 in Rome to assess
the reproducibility of PD-L1 scoring using e-learning solutions. In this study, we share the results
of this initiative, focusing on the reliability and affordability of this “2.0 approach” in pathology
clinical practice.
2. Materials and Methods
2.1. Cases Selection
A panel of seven pathologists with broad experience in lung cancer pathology (MB, CD, GF, FF,
PG, AM, and GT) selected from the archives of their respective institutions representative NSCLC
histologic blocks, as an e-learning material. All cases were anonymized, and the study was fully
compliant with the local ethical guidelines and the declaration of Helsinki. The study group was
composed of 32 NSCLC cases, including 27 (84.4%) surgical resections and 5 (15.6%) biopsies. The latter
were obtained from either primary (n = 3; 60%) or metastatic (n = 2; 40%) sites. The molecular status of
epidermal growth factor receptor (EGFR), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) and
anaplastic lymphoma kinase (ALK) was retrieved from the clinical databases. The inclusion criteria
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were the following: adult patients (>18 years old); no previous neoadjuvant chemoradiotherapy
administered; PD-L1 testing available.
2.2. PD-L1 Status Assessment and Tissue Slides Digitalization
For each case, representative hematoxylin and eosin (H&E) and PD-L1 stained slides were digitized
using a ScanScope CS digital scanner (Aperio, Park Center Dr, Vista, CA, USA) at a 40x magnification.
The original PD-L1 protein expression was determined using tumor proportion score (TPS), i.e.,
the percentage of viable tumor cells showing partial or complete membrane staining at any intensity.
Then, PD-L1 status was clustered into three categories, namely, negative (TPS < 1%), low (TPS 1–49%),
and high (TPS ≥ 50%). In 23 (71.9%) cases PD-L1 staining was performed using companion diagnostic
22C3 pharmDx kit on Dako Autostainer, while in 9 (28.1%) cases using the SP263 Ventana kit and
OptiView DAB IHC detection kit on BenchMark platform, as recommended by the manufacturer. For
all cases, the PD-L1 TPS was re-assessed by the panel of pathologists by using the same classification
to obtain the final gold standard. To define tumor cells as positive for PD-L1 staining two different
approaches were adopted. Briefly, for the 22C3 clone, a complete circumferential or partial linear
membranous staining of tumor cells at any intensity was necessary to define as positive the tumor
cells, whereas any membranous and/or cytoplasmic immunoreactivity in tumor cells was considered
positive for the SP263 clone. Discordant cases were discussed by the panel of pathologists in order to
obtain a consensus.
2.3. E-Learning-Based PD-L1 Analysis Harmonization among General Pathologists
All cases were shared with 37 general pathologists who participated at the meeting using e-learning
platforms. The study participants were divided into seven groups (i.e., orange, red, violet, green,
yellow, pink, blue); each group was supervised by one pathologist from the expert panel as a tutor.
Within the working groups, each digital case was blindly scored by each pathologist individually (TESI
SPA, Milan, Italy). The automatic informatics system allowed each pathologist to express his TPS for
each case on a digital table within 10 min, subsequently closing the session and saving the relative
data. Finally, the informatics system stopped the timing and saved the data. A final consensus on TPS
was reached by collegial discussion and the second round of scores for the digital cases.
2.4. Statistical Analysis
All study data were digitally recorded and collected. Subsequently, inferential statistical analysis
was performed using Microsoft Excel embedded tools (EGR, FB, MJ). The inter- and intra-observer
reproducibility was assessed by using positive and negative percent agreement, sensitivity (or true
positive rate), specificity (or true negative rate), positive and negative predictive values. Ninety-five
percent of confidence intervals were computed for all measurements.
3. Results
In Table 1 the clinical-pathological features of the case series are summarized. From a histological
point of view, and according to the 2015 WHO classification of lung cancer, our series included 22
adenocarcinomas and 10 squamous cell carcinomas. Patients’ age ranged from 41 to 86 years old.
A higher number of male patients was reported (22 vs. 10).
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Table 1. Sample set.
CASE
Codes SEX AGE DIAGNOSIS ALK ROS1 EGFR
1 M 76 adenocarcinoma neg neg neg
2 M 76 adenocarcinoma neg neg neg
3 M 78 squamous cell carcinoma n.a. n.a. n.a.
4 F 76 adenocarcinoma neg neg neg
5 M 78 adenocarcinoma neg neg neg
6 F 54 adenocarcinoma neg neg neg
7 M 65 adenocarcinoma neg neg neg
8 M 67 squamous cell carcinoma n.a. n.a. n.a.
9 M 56 adenocarcinoma neg neg neg
10 M 68 adenocarcinoma neg neg neg
11 M 61 adenocarcinoma neg neg neg
12 M 74 adenocarcinoma neg neg neg
14 F 62 adenocarcinoma (liver mts) neg neg neg
15 M 70 adenocarcinoma (lymph node mts) neg neg neg
16 M 80 squamous cell carcinoma (biopsy) n.a. n.a. n.a.
17 M 64 squamous cell carcinoma (biopsy) n.a. n.a. neg
20 M 86 squamous cell carcinoma n.a. n.a. n.a.
22 M 75 adenocarcinoma neg neg neg
30 M 68 adenocarcinoma neg n.a. neg
33 M 71 squamous cell carcinoma n.a. n.a. n.a.
34 F 76 adenocarcinoma n.a. n.a. neg
35 F 63 adenocarcinoma neg n.a. neg
36 M 55 adenocarcinoma neg neg neg
37 F 74 squamous cell carcinoma n.a. n.a. n.a.
38 F 71 squamous cell carcinoma n.a. n.a. n.a.
41 F 41 adenocarcinoma neg neg neg
45 M 71 squamous cell carcinoma neg neg neg
50 F 62 adenocarcinoma neg neg neg
51 M 59 squamous cell carcinoma n.a. n.a. n.a.
52 M 78 adenocarcinoma neg neg neg
54 F 67 adenocarcinoma n.a. neg neg
55 M 72 adenocarcinoma neg neg neg
Abbreviations: ALK: Anaplastic Lymphoma Kinase; EGFR: Epidermal Growth Factor Receptor; F: female; M: male;
n.a.: not assessed; mts: metastasis; neg: negative; ROS1: ROS Proto-Oncogene 1, Receptor Tyrosine Kinase.
In 24 out of 32 selected cases (75.0%), the PD-L1 score was concordant between the original report
and the expert panel of pathologists (Supplementary Table S1). In the remaining 8 cases, an under
(n = 4) or over-estimation (n = 4) of positive tumor cells was reported. Seven cases were negative
for PD-L1 expression, 16 were considered to be intermediate expressors, and 9 were classified as
strong positive by the expert panel (Supplementary Table S1). The 37 learner pathologists, divided
into 7 groups, evaluated all the digital slides on a laptop (Supplementary Table S2). The complete
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agreement between the expert panel (gold standard) and the participants was reached in a range
of 37.5% (group red) to 78.1% of cases (group yellow); the average value was 57.1% (Table 2). A
minor disagreement (1 participant per group) was recorded in 16.1% of cases (average value). In
the red, orange, and green groups, two cases had no agreement with the referee scores. In Table 3,
TPS disagreements were stratified according to the clinical threshold of PD-L1 scoring. The higher
agreement rate among pathologists was obtained in PD-L1 high cases, with only 10.8% (36/333 instances)
of disagreements with the gold standard, mainly regarding a single challenging case (55.6%, 20/36
instances; n = 37). Conversely, the worst performance was achieved in PD-L1 negative cases, where
32.0% (83/259 instances) of disagreements was demonstrated. Figure 1 highlights some paradigmatic
challenging pitfalls due to the staining of macrophages in PD-L1 negative tumors (cases n. 10 and
n. 22). In the category of intermediate expressors, 21.3% (126/259 instances) of disagreements was
detected. In Figure 2, a spectrum of the possible reactions in cases near to the threshold between
the intermediate and strong expressors is shown (cases n. 33 and n. 51). The specific evaluation
of the participants’ performances is shown in Supplementary Table S2. The best performance of
correct interpretation was 93.8% (pathologist G2). No statistically significant difference in percentage
of disagreement (≥2 pathologists) with the gold standard was observed between adenocarcinomas
and squamous cell carcinomas (27.3% vs. 25.7%, Supplementary Table S3). A significant difference
emerged when considering the different clones adopted (Supplementary Table S4). A lower number of
discrepancies (≥2 pathologists) was highlighted in the 22C3 clone group (22.3%) than in the SP263 one
(38.1%, p = 0.01).
Table 2. This table reports a chromatic scale of the different diagnostic performances: green (all
the participants of the group agreed with the reference score), blue (1 discordant pathologist), and red
(≥2 discordant pathologists).
R (n = 5) Y (n = 5) O (n = 5) V (n = 5) B (n = 6) P (n = 6) G (n = 5)
1
2
3
4
5
6
7
8
9
10
11
12
45
14
15
16
17
41
20
22
54
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Table 2. Cont.
R (n = 5) Y (n = 5) O (n = 5) V (n = 5) B (n = 6) P (n = 6) G (n = 5)
52
50
37
55
30
33
34
35
36
38
51
Table 3. Cases are divided according to three cut-off: PDL1 negative, intermediate and strong expressors
with the aim of highlighting the most challenge cases.
(A) PD-L1 NEGATIVE CASES (n = 7)
Cases R (n = 5) Y (n = 5) O (n = 5) V (n = 5) B (n = 6) P (n = 6) G (n = 5)
3
6
10
22
30
35
36
(B) PD-L1 [1–49] expressorS (n = 16)
R (n = 5) Y (n = 5) O (n = 5) V (n = 5) B (n = 6) P (n = 6) G (n = 5)
1 > < < <
4 < <(3) >(1); <(1) <
9 <(3) > < <(3)
11 <(1); >(1) <(4) <(2) < <(4) <(2) <(5)
12 > >(2)
16 > > >
17 < <(3) <(4) <(2)
33 >
38 < <(2)
41 <(5)
45
50 >(3) >(2) >(2); <(1) >(4) >(4) >(2)
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Table 3. Cont.
(B) PD-L1 [1–49] expressorS (n = 16)
51 >(5) >(3) >(3); <(1) >(5) >(2) >
52 >(4) >(5) >(3) >(2) >3
54 >(4) >(1); <(1)
55 >
(C) PD-L1 STRONG POSITIVE (n = 9)
R (n = 5) Y (n = 5) O (n = 5) V (n = 5) B (n = 6) P (n = 6) G (n = 5)
2
5
7
8
14
15
20
34
37
Cancers 2020, 12, 1800 8 of 16
Cancers 2020, 12, x FOR PEER REVIEW 5 of 15 
 
between adenocarcinomas and squamous cell carcinomas (27.3% vs 25.7%, Supplementary Table S3). 
A significant difference emerged when considering the different clones adopted (Supplementary 
Table S4). A lower number of discrepancies (≥2 pathologists) was highlighted in the 22C3 clone group 
(22.3%) than in the SP263 one (38.1%, p = 0.01) 
 
Figure 1. Negative cases. Exemplificative false positive background in macrophages and 
inflammatory cells in a lung biopsy. Case n. 10 (original magnification 10×, 22c3): PDL1 TPS < 1%; 
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Figure 1. Negative cases. Exemplificative false positive background in macrophages and inflammatory
cells in a lung biopsy. Case n. 10 (original magnification 10×, 22c3): PDL1 TPS < 1%; look at
the background staining in macrophages peritumoral cells. CASE n. 22 (10×, 22c3): PDL1 TPS < 1%;
the application of a careful magnification rule allows to classify as macrophages this group of PD-L1
strong positive cells.
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heterogeneous PD-L1 expression throughout the same tumor, with areas only showing faint 
background staining in non-neoplastic cells (bottom row, left) along with areas characterized by 
strong and complete membrane staining in the cancerous elements (bottom row, right). A challenging 
decision was jointly obtained to decide the exact threshold. Case n. 14 (10×, 22c3): PD-L1 TPS > 50%; 
all participants correctly ascribed this case to the ‘strong expression’ category due to the diffuse 
presence of PD-L1 staining in the tumor cells. Case n. 51 (10×, SP263): PD-L1 TPS 1–49%; 
heterogeneous PD-L1 expression with strong staining cells closely intermixed with faintly staining or 
negative cells. Case n. 33 (10×, 22C3): PD-L1 TPS 1–49%; a few of the neoplastic elements from this 
Figure 2. Intermediate and strong positive cases. Case n. 37 (10×, SP263): PD-L1 TPS > 50%;
heterogeneous PD-L1 expression throughout the same tumor, with areas only showing faint background
staining in non-neoplastic cells (bottom row, left) along with areas characterized by strong and complete
membrane staining in the cancerous elements (bottom row, right). A challenging decision was jointly
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obtained to decide the exact threshold. Case n. 14 (10×, 22c3): PD-L1 TPS > 50%; all participants
correctly ascribed this case to the ‘strong expression’ category due to the diffuse presence of PD-L1
staining in the tumor cells. Case n. 51 (10×, SP263): PD-L1 TPS 1–49%; heterogeneous PD-L1
expression with strong staining cells closely intermixed with faintly staining or negative cells. Case
n. 33 (10×, 22C3): PD-L1 TPS 1–49%; a few of the neoplastic elements from this poorly differentiated
adenocarcinoma showed a moderate membrane staining with the antibody, so this case was classified
as an example of ‘intermediate expression’.
4. Discussion
Digital pathology technologies for educational, diagnostic, and research purposes are rapidly
replacing the use of static images in this era of next-generation pathology. Digitalization of histologic
or cytologic slides ensures the possibility to cover the entire slide surface, enabling pathologists to
analyze the whole section as with the “traditional” microscope [2]. The application of e-learning
during an educational pathology course may reduce the subjectivity and variability of semiquantitative
analysis (by using dedicated software) and makes it possible to share interesting or challenging cases
for a second opinion [17]. However, despite these possibilities several issues remain unsolved. In
particular, efforts have to be devoted to validating the use of digital slides, as reported by The College
of American Pathologists (CAP) and the Digital Pathology Association (DPA) guidelines [17,18]. In
addition, a not negligible percentage of pathologists feel a lower compliance with digital diagnosis
respect to classical microscope evaluation [17]. The gradual introduction of similar tools during
informal meetings and courses may help in decreasing the reluctance of pathologists in accepting
the digital slides as an option and not an enemy. The development of user-friendly platforms that
contribute to the transformation of the traditional vertical didactic exposition of paradigmatic cases
into more dynamic and quiz-like experiences is currently available especially to approach single-item
issues like the evaluation of a tissue biomarker.
In the era of personalized medicine, immunotherapy with anti-PD-1/PD-L1 monoclonal antibodies
represents a relevant clinical option for patients with advanced stage NSCLC [19]. In particular, taking
into account the results that have been reported in KEYNOTE 024 and 042 clinical trials, the adoption
of pembrolizumab should be considered as the first line or as a valid second line treatment in advanced
stage NSCLC patients harboring a PD-L1 expression level ≥50% or between 1–49%, respectively [20,21].
Despite the improvements in molecular techniques, IHC still plays a key role in the evaluation of PD-L1
expression, in order to administer immunotherapy in this setting of patients. However, careful attention
should be paid due to extreme intra- and inter-observer variability in the staining interpretation, in
particular due to disparities in the training of pathologists [22]. In this setting, digital scanning of
selected challenging cases and collegial discussion with a panel of highly trained pathologists may
have an educational aim, helping pathologists to better define the expression level of PD-L1 and to
ensure the best treatment choice for advanced stage NSCLC patients.
After 3 years of routine testing in the laboratories, this paper focused on the challenges in
PD-L1 staining score evaluation among different pathologists by adopting digital slides. Despite
a good technical confidence generally being achieved, as demonstrated in previous reports [5], several
interpretative issues are remaining unsolved. To overcome these issues, a panel of seven expert
pathologists and a large group of pathologists joined a meeting that raised the main diagnostic issues in
specific challenging situations. All cases were re-evaluated by the panel of experts, and, after a collegial
discussion, in a high percentage of cases (75.0%) an agreement with the score referred in the original
report was reached.
Several pre-analytical factors may influence PD-L1 staining score evaluation. Different IHC
protocols (i.e., type and duration of antigen retrieval, primary antibody dilution or incubation time,
number of steps of amplification) are adopted by diverse laboratories, even when the same primary
antibody is used on the same platform with the same detection kit [23,24]. Since recent literature data
reported an acceptable overlapping between 22C3 PharmDx clone on Dako Autostainer or SP263
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clone on BenchMark platform, the panel enrolled NSCLC cases indifferently stained by using these
clones [5]. The SP263 clone demonstrates higher sensitivity than all other assays, but its specificity
was lower [19]. A comprehensive meta-analysis showed the sensitivity of PD-L1 IHC 22C3 pharmDx
superior than PD-L1 IHC 28-8 pharmDx and then Ventana PD-L1 (SP263) [24]. Other studies have
evaluated the interchangeability of PD-L1 assays [10]. However, no data are available in prospective
clinical trials. From the patient’s perspective, lower specificity may be acceptable if the progression
free survival, overall survival, and adverse effects in patients with PD-L1-negative tumors treated
by immunotherapy are comparable to that of conventional chemotherapy [25]. The employment of
Ventana platform usually produces more intense immunoreactivity, although the morphological detail
of the background tissue is not always well preserved, representing a possible issue in the distinction
among tumor and the immune cells (usually alveolar macrophages). On the other hand, the Dako
platform provides fairly soft immunoreactions with a better definition of the morphological features
of the different cell types [26]. Although the selection of the cases enrolled in the study reflected
the normal routine cases, the choice aimed to highlight the intra- and inter-tumoral heterogeneity of
PD-L1 expression, which may affect the reproducibility of this analysis (Figure 2). For this reason,
challenging borderline cases, characterized by a PD-L1 expression close to the proposed threshold,
were included.
To better represent the routine diagnostic cases, the panel selected a mixture of small specimens
(bronchoscopy and core needle biopsies), and surgical specimens of NSCLC with different histotypes
and respective molecular findings (Table 1). Results were compared with the TPS assigned by the panel
of experts (gold standards). The project highlighted interpretative inaccuracies potentially leading to
false negative results like the suboptimal application of the magnification rule, which recommends
the use of a high-power field for the scoring of mild/focal immunoreactivity [27]. On the contrary,
a false positive background was a frequent source of pitfalls due to macrophages staining (Figure 1).
Unspecific peri-membranous reactivity in mucous-rich adenocarcinomas may be an additional source
of errors for pathologists.
An important issue was related to the evaluation of viable tumor cells. Analytical interpretation of
PD-L1 staining score resulted in a false negative result if the pathologists did not establish the specimen
adequacy of the tumor sample defined by at least 100 viable neoplastic cells. Another relevant aspect is
the staining under-estimation when incomplete tumor membrane staining was evaluated. In previous
reports, Cohen’s κ coefficient was 0.68 (95% CI, 0.65–0.71) for the 1% cut point sample set, indicating
improvable inter-observer agreement in this subgroup of patients [28]. Conversely, in our series in
strong positive patients a large agreement was recorded with only 10.8% of disagreements (Table 3).
When considering a positive tumor cell staining around 50%, only a careful and extensive quantitative
evaluation may avoid an under-estimation. Moreover, the intensity of PD-L1 staining in heterogeneous
cases produced questionable interpretations (Figure 2). Literature data of a similar project showed
a slightly lower 0.58 Cohen’s κ coefficient (95% CI, 0.55–0.62) for the 50% cut point sample set, indicating
moderate inter-observer agreement [28]. The lower reproducibility at the 50% cut point suggested
that training and external quality assessment programs should improve reproducibility of the samples
with ≥50% of stained cells, particularly as this cut point is used to select NSCLC patients for anti-PD1
therapy [28]. The misclassification of patients may lead to two orders of problems: patients who
do not receive the first line PD-1 blockade therapy, and patients who receive a treatment that is
not beneficial [29]. All interpretation issues were a potential concern for pathologists, regardless
the assay type [30]. In our study, a complete agreement between the expert panel evaluation (gold
standard) and the participants was reached in 57.1% of cases (average value, Table 2). A minor
additional disagreement was recorded in 16.1% of cases. The best performer featured 93.8% of correct
interpretation (Supplementary Table S2).
The present paper highlights once again the potential of digital pathology. The possibility of
sharing slides for educational purpose, to use WSI for agreement and quality control studies and
the implementation of a digital pathology workflow for primary histological diagnosis have been widely
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reported [1–3,29]. We are approaching the third revolution in pathology with the implementation
of the artificial intelligence (AI) tool even in the everyday practice with the possibility to combine
the use of digital pathology and AI tool to support pathologists in the diagnostic setting [30,31].
The possibility of predicting IHC findings directly from H&E slides has also been reported [32],
including the PD-L1 status by the developing of a deep learning model [33]. The obtained results were
robust to interpathologist variability, opening new possibilities for PD-L1 assessment, especially when
there is insufficient tissue for all the needed IHC and molecular tests.
5. Conclusions
In the educational setting, despite an initial reluctance, Italian pathologists’ welcome digital
slides as an opportunity to share opinions and challenging cases and evaluate specific biomarkers’
performances like PD-L1. The educational digital pathology meeting planned in Rome in 2019 stressed
the diagnostic challenges of the PD-L1 IHC testing, collecting NSCLC samples from the Italian national
laboratories network. Despite the small number of cases (n = 32) and the limited inter-observer
reproducibility due to the impossibility to compare the results before and after training, the projected
addresses some interpretative components underlying possible sources of disagreement related to
the PD-L1 testing. Due to the crucial role of PD-L1 TPS for the selection of patients for immunotherapy,
the identification of educational unconventional approaches as virtual slides to focus experiences and
give more detailed practical verifications of the standard quality reached may be a considerable option.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/7/1800/s1,
Table S1: Original PD-L1 evaluation, expert board consensus and prevalent scoring for every group; discrepancies
between the original evaluation and the panel are highlighted in orange; participants errors in yellow. Table S2:
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strong positive (red, TPS ≥50%). In the first row, the gold standard results recorded by the board of experts were
listed. In the following rows, for every pathologist who attended the meeting a progressive number and a colour
of identification corresponding to the table were assigned. (ie.e R1: red table, participant number 1). Table S3:
Performances by histotype. Table S4: Performances by clone.
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